Skip to main content
main-content

Clinical trial summary slides

Latest slide set

CANVAS trial program in patients with type 2 diabetes and high cardiovascular risk

Heart_pills

This downloadable slide set summarizes the design and results of the CANVAS and CANVAS-R trials, which investigated the effect of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, on the risk for major adverse cardiac events and progression of albuminuria, as well as its general efficacy and safety in patients with type 2 diabetes and an elevated cardiovascular risk.

Trials listed by publication date

06-12-2017 | Canagliflozin | Clinical trial summary slides | Collection

CANVAS trial program in patients with type 2 diabetes and high cardiovascular risk

This downloadable slide set summarizes the design and results of the CANVAS and CANVAS-R trials, which investigated the effect of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, on the risk for major adverse cardiac events and progression of albuminuria, as well as its general efficacy and safety in patients with type 2 diabetes and an elevated cardiovascular risk.

09-16-2016 | Semaglutide (investigational) | Clinical trial summary slides | Collection

SUSTAIN-6 trial in patients with type 2 diabetes

This downloadable slide set summarizes the design and results of the SUSTAIN-6 study, which investigated the cardiovascular safety of the glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes.

06-13-2016 | Liraglutide (T2DM) | Clinical trial summary slides | Collection

LEADER trial in patients with type 2 diabetes

This downloadable slide set summarizes the design and results of the LEADER study, a cardiovascular safety trial of the glucagon-like peptide-1 receptor agonist liraglutide in patients with type 2 diabetes.

12-03-2015 | Lixisenatide | Clinical trial summary slides | Collection

ELIXA trial in patients with type 2 diabetes

This downloadable slide set summarizes the design and results of ELIXA, a cardiovascular outcomes study of the glucagon-like peptide-1 receptor agonist lixisenatide in patients with type 2 diabetes.

11-26-2015 | Empagliflozin | Clinical trial summary slides | Collection

EMPA-REG OUTCOME trial in patients with type 2 diabetes

This downloadable slide set summarizes the design and results of the EMPA-REG OUTCOME study, a cardiovascular safety study of the sodium-glucose cotransporter 2 inhibitor empagliflozin in patients with type 2 diabetes.

07-16-2015 | Sitagliptin | Clinical trial summary slides | Collection

TECOS trial in patients with type 2 diabetes

This downloadable slide set summarizes the design and results of TECOS, a cardiovascular outcomes study of the dipeptidyl peptidase-4 inhibitor sitagliptin in patients with type 2 diabetes.

10-03-2013 | Alogliptin | Clinical trial summary slides | Collection

EXAMINE trial in patients with type 2 diabetes

This downloadable slide set summarizes the design and results of the EXAMINE study, which investigated the cardiovascular safety of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with type 2 diabetes and acute coronary syndromes.

09-02-2013 | Saxagliptin | Clinical trial summary slides | Collection

SAVOR-TIMI 53 trial in patients with type 2 diabetes

This downloadable slide set summarizes the design and results of SAVOR-TIMI 53, a cardiovascular outcomes study of the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes.

06-11-2012 | Insulin glargine | Clinical trial summary slides | Collection

ORIGIN trial in patients with type 2 diabetes

This downloadable slide set summarizes the design and results of the ORIGIN study, which investigated the effect of titrated basal insulin glargine versus standard care and n-3 fatty acids versus placebo on cardiovascular (CV) outcomes in patients with (or at risk for) type 2 diabetes and other CV risk factors.

image credits